Study tests if cannabis Self-Medication theory holds up in schizophrenia

NCT ID NCT01964404

Completed Knowledge-focused Sponsor: Dartmouth-Hitchcock Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether cannabis or a similar drug (dronabinol) can improve brain reward function in people with schizophrenia who also use cannabis. 263 participants took part to see if these substances help regulate brain circuits linked to motivation and pleasure. The goal was to understand if cannabis acts as a form of self-medication for these patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANNABIS USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cannabis dependence psychotic disorder Psychotic Disorders schizophrenia substance-related disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CANNABIS USE DISORDER DUAL DIAGNOSIS PSYCHOTIC DISORDER SCHIZOPHRENIA

Contacts and locations

Locations

Dartmouth Hitchcock Medical Center

Lebanon, New Hampshire, 03756, United States
University of Vermont

Burlington, Vermont, 05401, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.